Compare · AXGN vs NRXS
AXGN vs NRXS
Side-by-side comparison of Axogen Inc. (AXGN) and Neuraxis Inc. (NRXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and NRXS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.54B, about 35.3x NRXS ($72.0M).
- Over the past year, AXGN is up 187.2% and NRXS is up 134.0% - AXGN leads by 53.2 points.
- NRXS has been more active in the news (13 items in the past 4 weeks vs 3 for AXGN).
- AXGN has more recent analyst coverage (9 ratings vs 0 for NRXS).
- Company
- Axogen Inc.
- Neuraxis Inc.
- Price
- $47.19+1.08%
- $5.71-2.73%
- Market cap
- $2.54B
- $72.0M
- 1M return
- -2.08%
- -17.19%
- 1Y return
- +187.19%
- +134.02%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- AMEX
- IPO
- 2023
- News (4w)
- 3
- 13
- Recent ratings
- 9
- 0
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Latest AXGN
- Director Tyndall Joseph A. sold $173,940 worth of shares (3,500 units at $49.70) as part of a pre-agreed trading plan, decreasing direct ownership by 25% to 10,650 units (SEC Form 4)
- Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
- Truist initiated coverage on AxoGen with a new price target
- EVP & General Counsel Began Marc A exercised 67,500 shares at a strike of $8.16 and sold $3,195,788 worth of shares (67,500 units at $47.34) as part of a pre-agreed trading plan (SEC Form 4)
- Director Wendell Amy Mcbride exercised 13,353 shares at a strike of $14.85 and sold $646,592 worth of shares (13,353 units at $48.42) as part of a pre-agreed trading plan (SEC Form 4)
- Director Weiler Kathy Johnson sold $640,967 worth of shares (14,150 units at $45.30) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
- SEC Form 10-Q filed by Axogen Inc.
- Axogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology
Latest NRXS
- iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
- CMO, SVP Science & Tech Miranda Adrian was granted 199,106 shares (SEC Form 4) to satisfy tax liability
- CRO, CCO, CPO Carrico Thomas Joeseph was granted 193,678 shares, increasing direct ownership by 3,418% to 199,345 units (SEC Form 4) (tax liability)
- Chief Executive Officer Carrico Brian Allen was granted 199,188 shares, increasing direct ownership by 708% to 227,336 units (SEC Form 4) to satisfy withholding obligation
- Neuraxis Inc. filed SEC Form 8-K: Leadership Update, Other Events
- Director Watkins Bradley Mitchell was granted 26,073 shares, increasing direct ownership by 56% to 72,408 units (SEC Form 4)
- SEC Form 4 filed by CMO, SVP Science & Tech Miranda Adrian
- Director Keyser Jane Elizabeth was granted 26,073 shares, increasing direct ownership by 56% to 72,408 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Henrichs Timothy Robert
- Director Ferge Kristin A was granted 31,134 shares, increasing direct ownership by 87% to 67,072 units (SEC Form 4)